The material guidance cut and ensuing investigation create near-term uncertainty. Traders should monitor for further company disclosures on the revenue shortfall drivers (e.g., NARCAN demand weakness), potential litigation developments, and any additional guidance revisions. The stock is likely to remain under pressure until clarity emerges.
Price Chart
Executive Summary
Emergent BioSolutions cut its FY2026 revenue guidance to $645-$675 million from $720-$760 million (midpoint down $75M) and reduced adjusted EBITDA guidance to $130-$150 million from $155-$175 million. Levi & Korsinsky launched an investigation into potential securities law violations related to the adequacy of prior guidance. The 10% revenue guidance cut and accompanying legal risk are material negatives for the stock.
Key Financial Metrics
Key Facts
- FY2026 revenue guidance cut to $645-$675M from $720-$760M (midpoint reduction of $75M)
- FY2026 adjusted EBITDA guidance cut to $130-$150M from $155-$175M
- Guidance cut announced on August 5, 2026, after management reaffirmed $720-$760M on April 30, 2026
- Levi & Korsinsky is investigating potential securities law violations regarding prior guidance statements
- Stock price declined following the guidance cut on August 5, causing investor losses
Financial Impact
Revenue guidance midpoint reduced by $75M (approximately 10% of prior midpoint); adjusted EBITDA guidance midpoint reduced by $25M (approximately 15% of prior midpoint)
Risk Factors
- Potential securities class action lawsuit and legal costs
- Further revenue degradation if NARCAN demand weakness persists
- Loss of investor confidence and possible credit rating impact
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302847532 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | Press Release | $4.45 $5.68 | ▼ −27.64% | ▼ −28.70% | $6.29 (−41.35%) |
Jun 29, 2026 13w ago | 8-K | $8.46 $7.26 | ▼ −14.18% | ▼ −13.90% | $6.29 (−25.65%) |
Jun 4, 2026 17w ago | Press Release | $8.44 $8.28 | ▼ −1.90% | ▼ −0.52% | $6.29 (−25.47%) |
Apr 30, 2026 22w ago | Press Release | $8.47 $8.49 | ▲ +0.24% | ▼ −5.05% | $6.29 (−25.74%) |
Apr 30, 2026 22w ago | Insider Cluster | $8.23 $9.18 | ▲ +11.54% | ▲ +6.58% | $6.29 (−23.57%) |
Apr 29, 2026 22w ago | Press Release | $7.99 $9.18 | ▲ +14.89% | ▲ +8.85% | $6.29 (−21.28%) |
Apr 29, 2026 22w ago | Press Release | $7.99 $9.18 | ▲ +14.89% | ▲ +8.85% | $6.29 (−21.28%) |
Apr 28, 2026 22w ago | DEFA14A | $8.23 $9.13 | ▲ +10.94% | ▲ +5.47% | $6.29 (−23.57%) |
Apr 28, 2026 22w ago | Press Release | $8.23 $9.13 | ▲ +10.94% | ▲ +5.47% | $6.29 (−23.57%) |
Apr 27, 2026 22w ago | DEFA14A | $8.23 $9.13 | ▲ +10.94% | ▲ +5.47% | $6.29 (−23.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access